ATE433575T1 - Neurotransmission-störungen - Google Patents

Neurotransmission-störungen

Info

Publication number
ATE433575T1
ATE433575T1 AT01940736T AT01940736T ATE433575T1 AT E433575 T1 ATE433575 T1 AT E433575T1 AT 01940736 T AT01940736 T AT 01940736T AT 01940736 T AT01940736 T AT 01940736T AT E433575 T1 ATE433575 T1 AT E433575T1
Authority
AT
Austria
Prior art keywords
neurotransmission
bodily fluid
developmental disorders
mammal
musk
Prior art date
Application number
AT01940736T
Other languages
English (en)
Inventor
Angela Vincent
Werner Hoch
Original Assignee
Isis Innovation
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE433575(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Innovation, Max Planck Gesellschaft filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE433575T1 publication Critical patent/ATE433575T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01940736T 2000-06-16 2001-06-15 Neurotransmission-störungen ATE433575T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0014878.3A GB0014878D0 (en) 2000-06-16 2000-06-16 Neurotransmission disorders
PCT/GB2001/002661 WO2001096601A2 (en) 2000-06-16 2001-06-15 Neurotransmission disorders

Publications (1)

Publication Number Publication Date
ATE433575T1 true ATE433575T1 (de) 2009-06-15

Family

ID=9893880

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01940736T ATE433575T1 (de) 2000-06-16 2001-06-15 Neurotransmission-störungen

Country Status (9)

Country Link
US (2) US7267820B2 (de)
EP (1) EP1327147B1 (de)
AT (1) ATE433575T1 (de)
AU (1) AU2001274239A1 (de)
CA (1) CA2455271C (de)
DE (1) DE60138958D1 (de)
ES (1) ES2327100T3 (de)
GB (1) GB0014878D0 (de)
WO (1) WO2001096601A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0014878D0 (en) * 2000-06-16 2000-08-09 Isis Innovation Neurotransmission disorders
CA2778478C (en) 2009-10-21 2018-06-19 Georgia Health Sciences University Research Institute, Inc. Detection and treatment of lrp4-associated neurotransmission disorders
GR1007341B (el) 2010-04-21 2011-07-05 ΕΛΛΗΝΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΠΑΣΤΕΡ (κατά ποσοστό 40%), Διαγνωστικος προσδιορισμος
JP6240919B2 (ja) * 2014-04-03 2017-12-06 地方独立行政法人東京都健康長寿医療センター 加齢または筋萎縮の診断用バイオマーカー
US10093743B2 (en) * 2014-11-18 2018-10-09 Premkumar Christadoss Muscle specific tyrosine kinase-fluorophore conjugate compositions, kits and methods of using
WO2020055241A1 (en) 2018-09-10 2020-03-19 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) Musk activation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814478A (en) * 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB0014878D0 (en) * 2000-06-16 2000-08-09 Isis Innovation Neurotransmission disorders

Also Published As

Publication number Publication date
WO2001096601A2 (en) 2001-12-20
GB0014878D0 (en) 2000-08-09
US7732147B2 (en) 2010-06-08
US20080057524A1 (en) 2008-03-06
CA2455271C (en) 2012-10-16
WO2001096601A3 (en) 2002-03-28
ES2327100T3 (es) 2009-10-26
EP1327147B1 (de) 2009-06-10
AU2001274239A1 (en) 2001-12-24
US7267820B2 (en) 2007-09-11
CA2455271A1 (en) 2001-12-20
DE60138958D1 (de) 2009-07-23
EP1327147A2 (de) 2003-07-16
US20040082010A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
BRPI0410261B8 (pt) anticorpo monoclonal que se liga especificamente ao probnp, métodos para detecção específica de probnp in vitro e para diagnóstico de insuficiência cardíaca in vitro, kit para medição de probnp, e linhagem celular de hibridoma mab 1.21.3
DK0914155T3 (da) Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen
DE60335022D1 (de) Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel
DK0540573T3 (da) Assay for frit- og kompleksbundet prostataspecifikt antigen (PSA)
SE9502196D0 (sv) Ultrasensitive immunoassays
RU2005131842A (ru) Моноклональное антитело и продуцирующая его гибридома
NZ288235A (en) Monoclonal antibody directed against the receptor tyrosine kinase flt4 and use in diagnosis and therapy
ATE487946T1 (de) Analytischer sandwichtest zur bestimmung von nt- probnp
NZ330475A (en) Antibodies, and use thereof in measuring lipid peroxidation in biological samples and method for inducing inflammation
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
RU2017114626A (ru) Антитело, связывающее линейный эпитоп человеческого р53, и его применение в диагностике
ATE433575T1 (de) Neurotransmission-störungen
DE50011181D1 (de) Nachweis des pyruvatkinase-isoenzyms im stuhl
EP1476757A4 (de) Verfahren und kit zur krebsvorhersage
ATE282830T1 (de) Immuntest für human chromogranine a (cga), antikörper, reagenz und dazu geeigneter testsatz
EP1245957A3 (de) Methode zur Konzentrationsbestimmung von Ceruloplasmin in einem Blutflecken mittels enzymgekoppeltem Immunosorbent-Assay oder mittels dissoziationsverstärktem, zeitaufgelöstem Immunofluoreszenzassay, sowie Kit zum Auffinden der Wilson-Krankheit und Diagnosemethode für letztere
SE0202702D0 (sv) Immunoassays for specific determination of SCCA isoforms
CA2346406A1 (en) Detection of pleiotrophin
SE0100595D0 (sv) Immunological detection of prostate diseases and prostatic-related diseases
KR870002453A (ko) 프로좀 단백질에 대한 단일항체의 제조방법 및 그를 이용한 프로좀과 관련된 현상의 검출 및 질병의 진단법
DE50304756D1 (de) Verfaren zur diagnose von neoplasmen
EP0364971A3 (de) Verfahren zum Nachweis der Legionella-Antigene in Körperflüssigkeiten und dergleichen und eine Testzusammensetzung zur Durchführung des Verfahrens
FI20011517A0 (fi) Menetelmä alkoholinkulutuksen osoittamiseksi, menetelmässä käytettäviä välineitä sekä niiden valmistus
ATE290694T1 (de) Diagnose von autoimmun-nebennierenkrankheit
IT1317355B1 (it) Anticorpi policlonali.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties